摘要
目的观察吉西他滨加希罗达方案治疗晚期胰腺癌的客观疗效及其临床受益反应(CBR)。方法对26例晚期胰腺癌患者给予此方案化疗3个周期,按WHO标准评定疗效及不良反应,同时综合评估临床受益率指标:疼痛、体力状况及体重变化。结果有效率(CR+PR)为29.1%,参照CBR综合指标,CBR率66.7%,不良反应主要为骨髓抑制和胃肠反应。结论吉西他滨加希罗达是治疗晚期胰腺癌的一种安全有效的化疗方案。
Objective To evaluate the clinical efficacy and CBR of chemotherapy with gemcitabine and xeloda in treatment of advanced pancreatic cancer. Method Twenty-six patients was treated with this regimen for 3 cycle. The efficacy and side effect were evaluated according to the WHO criterion, and the indexes of CBR including ache, physical strength and body weight were also evaluated. Result Response rate （CR ＋PR） was 29.1%. With neference to the integrated indexes of CBR, the CBR rate 66.7%. The adverse reaction was mainly bone marrow suppression and gastroenteric side effects. Conclusion Gemeitabine combined with xeloda for treatment of advanced pancreatic cancer is a kind of effective and safe regimen of chemotherapy.
出处
《中国肿瘤临床与康复》
2005年第6期558-560,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
